ABBOTINDIA:NSE-Abbott India Limited (INR)

COMMON STOCK | Drug Manufacturers—General | NSE

Last Closing Price

INR 16,318.20

Change

+80.45 (+0.50)%

Market Cap

INR 344.72B

Volume

6.71K

Average Target Price

INR 18,937.25 (+16.05%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolics, central nervous system, pain management, nutritional supplements, vitamins, insomnia, vaccines, consumer health, etc. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. Abbott India Limited was founded in 1944 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Laboratories Address: Godrej BKC, Mumbai, India, 400051

Employees : 3,551

Currency: INR

Country : India

Technical Indicators

Beta : 0.00

52 Week High : 18,679.75

52 Week Low : 10,350.00

200 Day Moving Average : 16,220.83

50 Day Moving Average : 16,587.84

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Drug Manufacturers—General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CIPLA:NSE Cipla Limited

+4.70 (+0.61%)

 INR620.41B 35.97 16.72
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-25.80 (-0.95%)

 INR460.16B 39.84 21.00
GLAXO:NSE GlaxoSmithKline Pharmaceutical..

+33.25 (+2.15%)

 INR261.38B 331.91 80.94
PFIZER:NSE Pfizer Limited

+97.55 (+1.98%)

 INR225.99B 42.88 26.61
SANOFI:NSE Sanofi India Limited

-29.55 (-0.35%)

 INR195.87B 43.34 25.00
MARKSANS:NSE Marksans Pharma Limited

+2.35 (+4.95%)

 INR19.44B 12.78 7.97
SMSPHARMA:NSE SMS Pharmaceuticals Limited

+3.05 (+3.46%)

 INR7.46B 23.46 10.59
TTKHLTCARE:NSE TTK Healthcare Limited

+0.75 (+0.16%)

 INR6.50B 102.84 19.51
KOPRAN:NSE Kopran Limited

+4.15 (+4.97%)

 INR3.61B 11.06 7.38
KILITCH:NSE Kilitch Drugs (India) Limited

-1.20 (-1.46%)

 INR1.26B 145.91 24.18

ETFs Containing ABBOTINDIA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—General)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.19% 55% F 75% C
Dividend Return 1.09% 100% A+ 67% D+
Total Return 25.28% 55% F 76% C
Trailing 12 Months  
Capital Gain 54.00% 55% F 86% B
Dividend Return 1.35% 100% A+ 72% C-
Total Return 55.34% 55% F 86% B
Trailing 5 Years  
Capital Gain 187.20% 100% A+ 91% A-
Dividend Return 5.60% 90% A- 54% F
Total Return 192.80% 100% A+ 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 35.63% N/A N/A 90% A-
Dividend Return 0.78% N/A N/A 53% F
Total Return 36.41% N/A N/A 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 40.76% N/A N/A 47% F
Risk Adjusted Return 89.32% N/A N/A 97% A+
Market Capitalization 344.72B 82% B- 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—General)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 51.74 36% F 16% F
Price/Book Ratio 13.97 18% F 3% F
Price / Cash Flow Ratio 55.06 18% F 5% F
EV/EBITDA 34.36 18% F 12% F
Management Effectiveness  
Return on Equity 26.71% 100% A+ 94% A
Return on Invested Capital 22.38% 100% A+ 94% A
Return on Assets 13.43% 100% A+ 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.00 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.